ArticleBMC cardiovascular disorders2025
Proteome-wide Mendelian randomization identifies drug targets for atrial fibrillation/flutter.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundDeveloping effective and safe drug targets for atrial fibrillation/flutter (AF/AFL) is a critical clinical need. As the plasma proteome represents a major source of druggable targets, this study aimed to identify causal protein targets for AF/AFL and assess their potential side effects.
methodsA two-sample Mendelian Randomization (MR) study was conducted to evaluate the causal effects of plasma proteins from the UK Biobank Pharma Proteomics Project (UKB-PPP) and the deCODE database on the risk of AF/AFL. The MR findings were further confirmed through Bayesian colocalization and Transcriptome-Wide Association Studies (TWAS) analyses. Furthermore, phenome-wide association study (PheWAS) was conducted to depict potential side effects of druggable targets, and Multivariable MR (MVMR) explored the potential mediators.
resultsMR analysis identified 44 plasma proteins from the UKB-PPP database and 14 from the deCODE database significantly associated with AF/AFL, and only 3 proteins (NFKB1, PGD, PCSK9) were overlapped. Colocalization analysis further identified only PCSK9 (Proprotein convertase subtilisin/kexin type 9) shared a causative genetic variant with AF/AFL (PP.H4 > 0.8). TWAS analysis also provided strong evidence to the association between PCSK9 and risks of AF/AFL. PheWAS have shown several potential side effects of PCSK9 inhibition (p_fdr < 0.05). Moreover, MVMR analysis revealed that LDL-C, systolic/diastolic blood pressure, and inflammatory factors may exert partial mediation effects on the causal relationship between PCSK9 and AF/AFL.
conclusionThis study identifies PCSK9 as a promising therapeutic target for AF/AFL, supported by consisitent evidence from MR, Bayesian colocalization, and TWAS analysis. And LDL-C, blood pressure, and inflammatory factors may exert partial mediation effects on the causal relationship between PCSK9 and AF/AFL.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.